Ultimovacs ASA (OSL: ULTI)
2.740
+0.035 (1.29%)
Aug 30, 2024, 4:25 PM CET
Ultimovacs ASA Company Description
Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway.
Its lead product candidate is UV1, a peptide-based therapeutic cancer vaccine that induces a specific T cell response against the pan-tumor antigen telomerase.
Ultimovacs ASA was incorporated in 2011 and is headquartered in Oslo, Norway.
Ultimovacs ASA
![Ultimovacs ASA logo](https://img.stockanalysis.com/logos1/OL/ULTI.png)
Country | Norway |
Founded | 2011 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 27 |
CEO | Carlos de Sousa |
Contact Details
Address: Ullernchausséen 64 Oslo, 0379 Norway | |
Phone | 47 41 38 00 80 |
Website | ultimovacs.com |
Stock Details
Ticker Symbol | ULTI |
Exchange | Oslo Børs |
Fiscal Year | January - December |
Reporting Currency | NOK |
ISIN Number | NO0010851603 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dr. Carlos de Sousa | Chief Executive Officer |
Hans Vassgard Eid | Chief Financial Officer |
Ingunn Hagen Westgaard Ph.D. | Head of Research |
Audun Tornes | Chief Technology Officer |
Jens Egil Torbjorn Bjorheim M.D., Ph.D. | Chief Medical Officer |
Oivind Foss Ph.D. | Head of Clinical Operations |
Antonius Berkien | Chief Business Officer |
Orla Mc Callion | Head of Regulatory Affairs and QA |
Prof. Gustav Gaudernack Ph.D. | Chief Scientific Officer |
Torill Trones | Head of Office |